Incidence of potential drug-drug interactions with antidiabetic drugs

Pharmazie

Volumn 70, Issue 6, 2015, Pages 410-415

  Samardzic, I ^a,b   Bacic Vrca, V ^b  

^a Community Pharmacy Gradska Ljekarna Zagreb ^*  (Croatia)

^b University of Zagreb   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; ATORVASTATIN; BISOPROLOL; CIPROFLOXACIN; CYTOCHROME P450 3A4; FUROSEMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIQUIDONE; GLUCOSE; HYDROCHLOROTHIAZIDE; IBUPROFEN; INSULIN; LOSARTAN; METFORMIN; PIOGLITAZONE; RAMIPRIL; REPAGLINIDE; SITAGLIPTIN;

AGED; ARTICLE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG DRUG INTERACTION; DRUG INTERACTION; DRUG MONITORING; DRUG UTILIZATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; ADULT; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; INCIDENCE; MIDDLE AGED; PHARMACY; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; PHARMACIES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84940734301     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2015.4777     Document Type: Article

References (48)

1. Agency for Medicinal Products and Medical Devices of Croatia, HALMED, Zagreb, Croatia: (2016) http://www.almp.hr/?ln=hr&w=publikacije&d=prometlijekova2012#Tablica3. Last accessed: 20th August 2014.
2. ALLHAT (2002) T The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997.
3. Bacic Vrca V, Becirevic-Lacan M, Bozikov V., Birus M (2005) Prescribing medicationerrorsinhospitalised patients:aprospective study. Acta Pharm 55: 157-167.
4. Bacic-Vrca V, Marusic S, Erdeljic V., Falamic S, Gojo-Tomic N, Rahelic D (2010) The incidence of potential drug-drug interactions in elderly patients with arterial hypertension. Pharm World Sci 32: 815-821.
5. Bailey CJ, Turner RC (1996) Metformin. N Engl J Med 334: 574-579.
6. Bjornsson TD, Callaghan JT, Einolf H.J., Fischer V., Gan L, Grimm S, Kao J., King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER) (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43: 443-469.
7. Cordonnier DJ, Zaoui P, Halimi S (2001) Role of ACE inhibitors in patients with diabetes mellitus. Drugs 61: 1883-1892.
8. Cruickshank JM (2002) Beta-blockers and diabetes: the bad guys come good. Cardiovasc Drugs Ther 16:457-470.
9. Danaei G, Finucane MM, Lu Y, Singh G.M., Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang Y.H., Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose) (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemio-logical studies with 370 country-years and 2.7 million participants. Lancet 378:31-40.
10. Fonseca VA (2010) Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin 26:615-629.
11. Freeman JS, Gross B (2012) Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review. Expert Rev Clin Pharmacol 5:31-42.
12. Gaede P, Lund-Andersen H, Parving H.H., Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580-591.
13. Giacomini KM, Huang SM, Tweedie D.J., Benet LZ, Brouwer KL, Chu X, Dahlin A., Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L (2010) Membrane transporters in drug development. Nat Rev Drug Discov. 9: 215-236.
14. Graumlich JF, Habis S, Avelino R.R., Salverson SM, Gaddamanugu M, Jamma K, Aldag JC (2005) Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy 25: 1296-1302.
15. Halkin H, Katzir I, Kurman I., Jan J, Malkin BB (2001) Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther 69: 260-265.
16. He F, Li Y, Zeng C., Xia C, Xiong Y, Zhang H., Huang S, Liu M (2014) Contribution of cytochrome P450 isoforms to gliquidone metabolism in rats and human. Xenobiotica 44: 229-234.
17. Inzucchi SE, Bergenstal RM, Buse J.B., Diamant M., Ferrannini E, Nauck M, Peters A.L., Tsapas A., Wender R, Matthews DR (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55: 1577-1596.
18. Ismail-Beigi F, Moghissi E, Tiktin M., Hirsch IB, Inzucchi SE, Genuth S (2011) Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 154: 554-559.
19. Juurlink DN, Mamdani M, Kopp A., Laupacis A, Redelmeier DA (2003) Drug-drug interactions among elderly patients hospitalized for drug tox-icity. JAMA 289: 1652-1658.
20. Klatt S, Fromm MF, Konig Jorg (2011) Transporter-mediated drug-drug interactions with oral antidiabetic drugs. Pharmaceutics 3: 680-705.
21. Lexi-Copm (2014) Lexi-Comp ONLINE. Lexi-Interact. Available at: http://online.lexi.com/crlsql/servlet/crlonline?a=in. Last accessed: 20th August 2014.
22. Lodise T, Graves J, Miller C., Mohr JF, Lomaestro B, Smith RP (2007) Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients. Pharmacotherapy 27: 1498-1505.
23. Mogensen CE (2003). New treatment guidelines for a patient with diabetes and hypertension. J Hypertens Suppl. 21: S25-30.
24. Mohr JF, McKinnon PS, Peymann P.J., Kenton I., Septimus E, Okhuysen PC (2005) A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 25: 1303-1309.
25. Morrish NJ, Wang SL, Stevens L.K., Fuller JH, Keen H (2001) Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44: 14-21.
26. Munger MA (2010) Polypharmacy and combination therapy in the management of hypertension in elderly patients with co-morbid diabetes mellitus. Drugs Aging 27: 871-883.
27. Neutel JM (1996) Metabolic Manifestations of Low-Dose Diuretics. Am J Med 101:71S-82S.
28. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ (2003) Effects of gem-fibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46: 347-351.
29. Peterson JF, Bates DW (2001) Preventable medication errors: identifying and eliminating serious drug interactions. J Am Pharm Assoc 41: 159-160.
30. Pirmohamed M, James S, Meakin S., Green C, Scott AK, Walley T.J., Farrar K., Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ 329: 15-19.
31. Poljicanin T, Metelko Z, Kolaric V., Sekerija M. National Diabetes Registry CroDiab. Report for 2012. Available at: http://hzjz.hr/wp-content/uploads/2013/11/crodiabreg2012.pdf. Last accessed: 20th August 2014.
32. Prescribing information. Glurenorm (gliquidone). Athens, Greece: (2016) Boehringer Ingelheim, 01/2012.
33. Rathmann W, Giani G (2003) Quality of prescription drug use in patients with type 2 diabetes mellitus in Germany. Dtsch Med Wochenschr 128: 1183-1186.
34. Reboldi G, Gentile G, Angeli F., Verdecchia P (2009) Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. Expert Rev Cardiovasc Ther 7: 1349-1361.
35. Ryden L, Grant PJ, Anker S.D., Berne C., Cosentino F, Danchin N et al. (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34: 3035-3087.
36. Salvetti A, Ghiadoni L (2006) Thiazide diuretics in the treatment of hypertension: an update. J Am Soc Nephrol 17 (4 Suppl 2): S25-29.
37. Sattar N, Preiss D, Murray H.M., Welsh P., Buckley BM, deCraen AJ, Seshasai SR, McMurray J.J., Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 375: 735-742.
38. Scheen AJ (2005) Drugs interactions of clinical importance with antihyper-glycaemic agents: an update. Drug Saf 28: 601-631.
39. Scheen AJ (2010) Dipeptidylpeptidase-4 inhibitors (gliptins): focusondrug-drug interactions. Clin Pharmacokinet 49: 573-588.
40. Schorr SG, Eickhoff C, Feldt S., Hohmann C, Schulz M (2014) Exploring the potential impact of hospital ward-based pharmacy interns on drug safety. Pharmazie 69: 316-320.
41. Shah RV, Goldfine AB (2012) Statinsand riskofnew-onset diabetes mellitus. Circulation 126: e282-e284.
42. Tornio A, Niemi M, Neuvonen P.J., Backman JT (2012) Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci 33: 312-322.
43. Turnbull F, Neal B, Algert C., Chalmers J, Chapman N, Cutler J., Woodward M, MacMahon S; Blood Pressure Lowering Treatment Trialists' collaboration (2005) Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mel-litus: results of prospectively designed overviews of randomized trials. Arch Intern Med 165: 1410-1419.
44. UK Prospective Diabetes Study Group (1998a) Tight blood pressure control and risk of macrovascular and microvascular complications in type II diabetes: UKPDS 38. BMJ 317: 703-713.
45. UK Prospective Diabetes Study Group (1998b) Efficacy ofatenolol and cap-topril in reducing risk of macrovascular and microvascular complications in type II diabetes: UKPDS 39. BMJ 317: 713-720.
46. Weir MR, Flack JM, Applegate WB (1996) Tolerability, safety, and quality of life and hypertensive therapy: the case for low-dose diuretics. Am J Med 101: 83S-92S.
47. Whiting DR, Guariguata L, Weil C., Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94: 311-321.
48. Yamada C, Nagashima K, Takahashi A., Ueno H, Kawasaki Y, Yamada Y., Seino Y, Inagaki N (2006) Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur J Pharmacol 553: 67-72.